Zolgensma is used to help treat spinal muscular atrophy (SMA) in children younger than 2 years old. The recommended dosage for children is 1.1 x 10 14 vg per kilogram (kg)* of body weight.

Zolgensma may cause elevated enzymes, which can lead to serious liver damage. If your child has a history of liver problems, they may be at a higher risk of developing this side effect.

Zolgensma: A Remarkable New Treatment, An ICER Analysis, And A Poorly Justified Price Peter B. Bach June 18, 2019 10.1377/forefront.20190617.50453 Sections ...

Zolgensma generated $634 million during the first half of the year, a 69% increase compared with 2020. The medicine is approved in more than 40 countries.

And, a value-based price for Zolgensma was estimated at between $1.2 million to $2.1 million, given an alternative threshold of $100,000 to $150,000 per life year gained.

Zolgensma is prescribed to treat SMA in certain children ages 2 years and younger. The dosage is based on the child’s body weight in kilograms (kg). For reference, 1 kg equals about 2.2 pounds (lb).